Menu
SOPHiA GENETICS is thrilled to be back at this year’s Healthcare Information and Management Systems Society annual meeting. Stop by booth #3460 to meet our team and to learn how our cloud-based SOPHiA DDM™ Platform is empowering clinical researchers to break data silos and improve knowledge sharing. You can also chat with our experts and dem our SOPHiA DDM™ Platform GEN 2. Stay tuned for more information on our Lunch & Learn presentation.
Lunch & Learn
Wednesday, March 5, 2025
12:30 PM - 1:45 PM PT
Caesars Forum
Forum 121
Optimizing genomic analysis workflows by streamlining system integration
Jitin Asnaani, Chief Product Officer, Rhapsody
Wiley Gellar, Senior Product Manager, SOPHiA GENETICS
Next-generation sequencing (NGS) is becoming more cost-effective, delivering deeper actionable insights and driving advancements in precision medicine. However, its rapid growth and increasing adoption in healthcare present significant challenges. Traditional data management methods often operate in silos, resulting in time-consuming processes, limiting scalability, and delaying access to critical insights. In healthcare, the challenge is twofold: it is paramount that sensitive patient data remains highly secure while also being readily accessible to guide time-sensitive decision-making.
To meet these demands and streamline genomic workflows, SOPHiA GENETICS joined forces with Rhapsody to develop an edge-deployed integration container for rapid deployment and seamless system integration. Unlike traditional solutions, this approach intelligently places a smaller, containerized engine on client premises to ensure rapid movement of large genomic data sets. This architecture ensures robust security while enabling fast data movement of large Next Generation Sequencing files, providing effortless interoperability, and scalable, repeatable implementation with minimal complexity.
Attendees will explore key challenges and opportunities in deploying secure, scalable genomic workflows and improving access to actionable insights while ensuring data integrity and compliance.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
